464 related articles for article (PubMed ID: 30711630)
1. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
[TBL] [Abstract][Full Text] [Related]
2. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.
Yang F; Zheng X; Koh S; Lu J; Cheng J; Li P; Du C; Chen Y; Chen X; Yang L; Chen W; Wong RW; Wai LE; Wang T; Zhang Q; Chen W
Hepatol Int; 2023 Aug; 17(4):850-859. PubMed ID: 37067675
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients.
Hafezi M; Lin M; Chia A; Chua A; Ho ZZ; Fam R; Tan D; Aw J; Pavesi A; Krishnamoorthy TL; Chow WC; Chen W; Zhang Q; Wai LE; Koh S; Tan AT; Bertoletti A
Hepatology; 2021 Jul; 74(1):200-213. PubMed ID: 33249625
[TBL] [Abstract][Full Text] [Related]
4. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan.
Tamori A; Nishiguchi S; Kubo S; Narimatsu T; Habu D; Takeda T; Hirohashi K; Shiomi S
J Med Virol; 2003 Dec; 71(4):492-8. PubMed ID: 14556260
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.
Meng F; Zhao J; Tan AT; Hu W; Wang SY; Jin J; Wu J; Li Y; Shi L; Fu JL; Yu S; Shen Y; Liu L; Luan J; Shi M; Xie Y; Zhou CB; Wong RW; Lu-En W; Koh S; Bertoletti A; Wang T; Zhang JY; Wang FS
Hepatol Int; 2021 Dec; 15(6):1402-1412. PubMed ID: 34850325
[TBL] [Abstract][Full Text] [Related]
6. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.
Gehring AJ; Xue SA; Ho ZZ; Teoh D; Ruedl C; Chia A; Koh S; Lim SG; Maini MK; Stauss H; Bertoletti A
J Hepatol; 2011 Jul; 55(1):103-10. PubMed ID: 21145860
[TBL] [Abstract][Full Text] [Related]
7. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma.
Liu Q; Tian Y; Li Y; Zhang W; Cai W; Liu Y; Ren Y; Liang Z; Zhou P; Zhang Y; Bao Y; Li Y
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323464
[TBL] [Abstract][Full Text] [Related]
8. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.
Tan AT; Meng F; Jin J; Zhang JY; Wang SY; Shi L; Shi M; Li Y; Xie Y; Liu LM; Zhou CB; Chua A; Ho ZZ; Luan J; Zhao J; Li J; Wai LE; Koh S; Wang T; Bertoletti A; Wang FS
Hepatol Commun; 2022 Apr; 6(4):841-854. PubMed ID: 34935312
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.
Kah J; Koh S; Volz T; Ceccarello E; Allweiss L; Lütgehetmann M; Bertoletti A; Dandri M
J Clin Invest; 2017 Aug; 127(8):3177-3188. PubMed ID: 28737510
[TBL] [Abstract][Full Text] [Related]
10. The role of previous infection of hepatitis B virus in Hbs antigen negative and anti-HCV negative Japanese patients with hepatocellular carcinoma: etiological and molecular biological study.
Matsuzaki Y; Sato M; Saito Y; Karube M; Doy M; Shoda J; Abei M; Tanaka N; Hadama T; Kinoshita M
J Exp Clin Cancer Res; 1999 Sep; 18(3):379-89. PubMed ID: 10606185
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.
Qasim W; Brunetto M; Gehring AJ; Xue SA; Schurich A; Khakpoor A; Zhan H; Ciccorossi P; Gilmour K; Cavallone D; Moriconi F; Farzhenah F; Mazzoni A; Chan L; Morris E; Thrasher A; Maini MK; Bonino F; Stauss H; Bertoletti A
J Hepatol; 2015 Feb; 62(2):486-91. PubMed ID: 25308176
[TBL] [Abstract][Full Text] [Related]
12. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
[TBL] [Abstract][Full Text] [Related]
13. Tumor eradication by hepatitis B virus X antigen-specific CD8+ T cells in xenografted nude mice.
Chun E; Lee J; Cheong HS; Lee KY
J Immunol; 2003 Feb; 170(3):1183-90. PubMed ID: 12538674
[TBL] [Abstract][Full Text] [Related]
14. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
[TBL] [Abstract][Full Text] [Related]
16. Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer.
Li CL; Ho MC; Lin YY; Tzeng ST; Chen YJ; Pai HY; Wang YC; Chen CL; Lee YH; Chen DS; Yeh SH; Chen PJ
Hepatology; 2020 Dec; 72(6):2063-2076. PubMed ID: 32171027
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma.
Saitta C; Tripodi G; Barbera A; Bertuccio A; Smedile A; Ciancio A; Raffa G; Sangiovanni A; Navarra G; Raimondo G; Pollicino T
Liver Int; 2015 Oct; 35(10):2311-7. PubMed ID: 25677098
[TBL] [Abstract][Full Text] [Related]
18. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive chimeric DNA profiling identifies tumor-originated HBV integrants contributing to viral antigen expression in liver cancer.
Chen W; Zhang K; Dong P; Fanning G; Tao C; Zhang H; Guo S; Wang Z; Hong Y; Yang X; Lai S; Ding H; Zhao H; Zeng C; Protzer U; Zhang D
Hepatol Int; 2020 May; 14(3):326-337. PubMed ID: 32100258
[TBL] [Abstract][Full Text] [Related]
20. [X protein variations of genotype B and C hepatitis B virus isolated from the patients with hepatocellular carcinoma].
Xu X; Chen WN; Zheng DL; Huang QL; Lin X
Ai Zheng; 2004 Jul; 23(7):756-61. PubMed ID: 15248907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
